Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9594 posts found.

Protherics raises

December 19, 2006 Research and Development

UK-based biotech company Protherics has raised £38 million, which will be split in a three-pronged move to expand its development …
News

GSK’s mock vaccine gets EU positive opinion

December 19, 2006 Research and Development

GlaxoSmithKline Biological's mock pandemic flu vaccine has received a positive opinion from EU regulators.Daronix is intended to protect against flu …
News

National cancer network underpins prostate vaccine trial

December 11, 2006 Research and Development

The UK's National Cancer Research Network has given its backing to a phase IIb trial of a promising vaccine for …
News

GSK buys antibody firm Domantis for

December 11, 2006 Research and Development

GlaxoSmithKline has bought Cambridge-based antibody firm Domantis for £230 million.Domantis, a leader in developing the next generation of antibody therapies, …
News

TroVax a step nearer to orphan status

December 8, 2006 Research and Development

Oxford BioMedica's leading cancer immunotherapy vaccine has received a positive opinion as an orphan drug for renal cancer from the …
News

Closer scrutiny for high-risk clinical trials

December 8, 2006 Research and Development

Wide-ranging changes will be made to the way clinical trials are conducted in the UK following the final report by …
News

New UK body to fast-track breakthrough research

December 8, 2006 Research and Development

Faster approval of NHS clinical trials and NICE recommendations are almost certain following a fundamental shake-up in the way UK …
News

Novartis readies Prexige for European launch

December 8, 2006 Research and Development, Sales and Marketing

Novartis will launch Prexige in its first European markets outside the UK next year following its EMEA approval for osteoarthritic …
News

Get the best from your R&D team

December 6, 2006 Business Services, Research and Development R&D, recruitment

One of the key drivers of much of the recent merger and acquisition activity within the pharmaceutical industry is the …
Feature

Cholesterol drug failure hits Pfizer

December 4, 2006 Research and Development, Sales and Marketing

Pfizer has suffered a major blow with its decision to cancel late-stage pipeline torcetrapib following safety concerns.Torcetrapib, which raises 'good' …
News

Takeover will create UK leader in pulmonary products

November 29, 2006 Research and Development, Sales and Marketing

Pulmonary product development in the UK has received a boost following the takeover by biotech company Vectura of the drug …
News

Merck looks to traditional medicine in cancer research

November 20, 2006 Research and Development

Merck is to collaborate with traditional medicine company Chi-Med to develop new small molecule anti-cancer drugs from natural products.Chi-Med, based …
News

Sanofi-Aventis to collaborate with French biotech company on Alzheimer’s disease

November 20, 2006 Research and Development

Pharma company Sanofi-Aventis has entered into a research agreement with a major French biotech firm to study the role of …
News

Future global R&D for Bayer Schering defined

November 17, 2006 Research and Development

Following the merger deal between German pharma companies Bayer and Schering earlier this year, the new corporation has unveiled radical …
News

UK biotech comes to market

November 10, 2006 Research and Development biotech, investment

At last, the signals are getting stronger that the biotechnology industry is poised and ready to tackle the publicly quoted …
Feature
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026